Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors.
about
Salicylic Acid Based Small Molecule Inhibitor for the Oncogenic Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2)Molecular Basis of Gain-of-Function LEOPARD Syndrome-Associated SHP2 MutationsShp2 confers cisplatin resistance in small cell lung cancer via an AKT-mediated increase in CA916798.Tyrosine phosphatase Shp2 mediates the estrogen biological action in breast cancer via interaction with the estrogen extranuclear receptor.Small molecule inhibitors of SHP2 tyrosine phosphatase discovered by virtual screening.SHP2E76K mutant promotes lung tumorigenesis in transgenic miceTherapeutic potential of targeting the oncogenic SHP2 phosphatase.Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11).Protein tyrosine phosphatases as potential therapeutic targets.Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesisThe language phenotype of children and adolescents with Noonan syndrome.Cancer risk in patients with Noonan syndrome carrying a PTPN11 mutation.Bicyclic benzofuran and indole-based salicylic acids as protein tyrosine phosphatase inhibitorsDiscovery of a Novel Inhibitor of the Protein Tyrosine Phosphatase Shp2.Increased expression of tyrosine phosphatase SHP-2 in Helicobacter pylori-infected gastric cancerSHP-2 tyrosine phosphatase in human diseases.Targeting SHP2 for EGFR inhibitor resistant non-small cell lung carcinoma.Noonan, Costello and cardio-facio-cutaneous syndromes: dysregulation of the Ras-MAPK pathway.Noonan syndrome - a new survey.SHP-2 phosphatase contributes to KRAS-driven intestinal oncogenesis but prevents colitis-associated cancer development.Targeting protein tyrosine phosphatase SHP2 for therapeutic intervention.SHP2 tyrosine phosphatase converts parafibromin/Cdc73 from a tumor suppressor to an oncogenic driver.The tumor suppressor role of Src homology phosphotyrosine phosphatase 2 in hepatocellular carcinoma.Regulatory Mechanisms and Novel Therapeutic Targeting Strategies for Protein Tyrosine Phosphatases.Amino acid polymorphisms flanking the EPIYA-A motif of Helicobacter pylori CagA C-terminal region is associated with gastric cancer in east China: experience from a single center.
P2860
Q27659942-A1BD177E-D819-44F7-9B64-95B40AD86214Q27684353-B6CD5B2B-10E7-414D-8FE0-2FF37467C12FQ33618818-FA014F0A-FFC1-4FA8-AAD1-44C091EAB122Q33928558-817A5E92-935E-40DD-A87F-D89A136562CEQ33931319-08457604-A7F5-4702-BA98-AFAE2EC43B6EQ34009953-1B5B5FF5-9AD3-46C1-B844-DF1DBE6B25D8Q34061302-45D4AC0E-BA5A-4445-A562-B63F0762590DQ34155125-008DE0B3-A0F9-4B40-A70D-6E4E2C6947C8Q34295063-7CB8ABCE-5360-440A-AD8A-9F334F2C794CQ34503441-72AEA896-3E82-4799-BB8A-7F3C4C0398EBQ34911307-9BB9EB72-3C29-42FA-90A7-514C52E4460DQ35212696-13BC9893-436B-43EC-BFDE-570A0B5821FAQ35815528-29169A1B-A5F5-4A15-9C9B-022BBDEA7C98Q36340315-E683248A-CAFB-43D8-9000-A1F553EC5C10Q36572533-BEB8AE39-0470-4AA9-8AC9-783AE0A8C503Q37186707-04002DDF-DC85-48A0-A575-443FD29055DFQ37293656-1684C54B-907B-49FE-9883-05DCEA35B61AQ37343475-C510192D-264D-4672-B492-F1E8E34EAD2BQ37549407-ACFAAFE9-01D4-4C62-B00C-436F9742F98DQ37662297-3B13FCEC-356B-46D1-8D17-5720743A0FB5Q38261370-20822397-C56E-4267-8F17-C7EEAD3E98C3Q41908225-1C9A132A-C7B8-421D-85AD-868DB15279A3Q44667833-5D5FFC8C-71A4-44FD-9809-B27923CD4C8DQ48103763-C92A7FE1-185D-42B6-A3B7-857E22BC5D63Q54267284-CE509F45-D203-41ED-BA45-FE018D0273A8
P2860
Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Isolation of a distinct class ...... ng activity from solid tumors.
@en
type
label
Isolation of a distinct class ...... ng activity from solid tumors.
@en
prefLabel
Isolation of a distinct class ...... ng activity from solid tumors.
@en
P2093
P2860
P356
P1433
P1476
Isolation of a distinct class ...... ng activity from solid tumors.
@en
P2093
A Takahashi
D Miyamoto
M Hatakeyama
M Miyamoto
Y Yomogita
P2860
P2888
P304
P356
10.1038/SJ.ONC.1211019
P407
P577
2008-01-28T00:00:00Z
P5875
P6179
1016134323